CytoMed Therapeutics Ltd(GDTC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.3M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
GDTC Stock Analysis & AI Quality Score
AI stock analysis and institutional research for CytoMed Therapeutics Ltd (GDTC), a Healthcare sector company. GDTC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.3m in revenue. Top institutional holders of GDTC by reported 13-F value include XTX Topco Ltd, UBS Group AG, OSAIC HOLDINGS,, based on the most recent SEC filings. GDTC trades on the Nasdaq exchange and files with the SEC under CIK 1873093. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GDTC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CytoMed Therapeutics Ltd directly from SEC EDGAR.
Get alerted when GDTC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CytoMed Therapeutics Ltd including:
Top Institutional Holders of GDTC
XTX Topco Ltd
$10.1K10,136 shUBS Group AG
$6.2K6,182 shOSAIC HOLDINGS, INC.
$21.0021 sh
| Fund | Value | Shares |
|---|---|---|
| XTX Topco Ltd | $10.1K | 10,136 |
| UBS Group AG | $6.2K | 6,182 |
| OSAIC HOLDINGS, INC. | $21.00 | 21 |
More Healthcare Companies
View all Healthcare →Put GDTC on your watchlist
Track score changes the day CytoMed Therapeutics Ltd files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GDTC a good stock to buy?
13F Pro's AI-powered analysis of CytoMed Therapeutics Ltd (GDTC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GDTC are available on the GDTC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own GDTC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GDTC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CytoMed Therapeutics Ltd's investment landscape.